The date was highlighted on Twitter by the Center for Genetic Engineering and Biotechnology (CIGB), creator of the drug that was applied at the time to 760 volunteers over 19 years of age at Saturnino Lora General Hospital in eastern province of Santiago de Cuba to prove its immunogenicity capacities.
Dr. Marta Ayala Ávila, CIGB general director, told the press back then that results of phase I trial started on December 7, 2020, revealed that safety markers of Abdala proved favorable for the doses studied, which allowed to speed up the start of the new stage.
Also playing an important role was the Business Group from the Biotechnology and Pharmaceutical Industries of Cuba (BioCubaFarma) being for nine years the leader of different research, development and business activities between the scientific entities of the country.
“Nine years being #BioCubaFarma. Today, December 7, we are celebrating our anniversary. All our workers, founders and collaborators be congratulated”, the entity wrote on Twitter.
BioCubaFarma has a portfolio of more than 400 projects, some aimed at obtaining specific products, while another line focuses on technology and scientific-technical services.
In this regard, Director of Science and Innovation, Rolando Pérez, indicated that the portfolio includes chemical-pharmaceutical and bio-pharmaceutical products, equipment and diagnostics, as well as productions devoted to agricultural biotechnology and natural medicine.
mh/lcr/mem/nmr
